Biopharmaceutical company Actinium Pharmaceuticals has received notice of patent allowance for an application covering the treatment of metastatic solid cancers with alpha emitting isotopes.
The patent application 'Alpha Emitting Constructs and Uses Thereof' is licensed by Actinium from Memorial Sloan Kettering Cancer Center.
Actinium CMO Dragan Cicic said the decision is important in advancing the company's technology to address the vast unmet medical need area of metastatic cancers in older patients.
"We have the potential to not only improve efficacy of cancer treatment but also enable it in many patients too sick to withstand the rigors of currently available therapies," Cicic added.
The treatment methods covered in the application use carriers of alpha emitting isotopes actinium 225 and bismuth 213 to target either cancer cells directly or blood vessels that facilitate their growth.
The issuance of patent is expected shortly.
